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ABSTRACT 
Objective: The objective of this study is to evaluate prescribing pattern, analyze drug-related problems, identify co-morbidities and complications 
in Type 2 Diabetes Mellitus patients and also to perform cost analysis of Biguanides, Sulfonylureas, Dipeptidyl Peptidase Inhibitors 
Methods: A Prospective observational study was done in General Medicine and Endocrinology Departments of PSG Hospitals. A total of 200 study 
subjects, including both inpatients and outpatients, above 18 y of age, prescribed with OHAs (Biguanides, Sulfonylureas and DPP4 inhibitors) were 
included in the study. 
Results: Diabetes was more prevalent among males. OHAs were most prescribed in the age group of 51-60 y. Hypertension (71%) was the most 
common comorbidity and Diabetic neuropathy (23%) was the most common complication found in the patients. Multidrug therapy (72.5%) was 
most prescribed in diabetic patients, followed by Biguanides. Hypoglycemia was the most prevalent ADR. Cost analysis showed that T. Linagliptin 
was of high cost and T. Glimepiride being the low cost. Using WHO core indicators prescribing patterns were assessed. Feedback was collected and 
results were reported to the physicians which showed rational utilization of drugs. 
Conclusion: The study on drug utilization conducted in a tertiary care hospital helped us to find out that prescribing trends seems to be progressing 
towards combination therapy, predominantly two-drug therapy 
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INTRODUCTION 
The term Diabetes describes a metabolic disorder of multiple 
etiology characterized by chronic hyperglycemia with disturbances 
of carbohydrates, fat and protein metabolism resulting from defects 
in insulin secretion, insulin action or both [1, 2]. 
Diabetes mellitus is a leading cause of morbidity and mortality 
because of its associated complications viz: Neuropathy, 
Nephropathy, Retinopathy, and cardiovascular disorders. The 
prevalence of type 2 Diabetes has been increasing worldwide as a 
result of excess body weight and physical inactivity. 
According to 2019 International Diabetes Federation survey of India, 
among 997 million population, 88 million (8.8%) people were 
reported to have Type 2 Diabetes Mellitus [3]. Indians are more 
prone to diabetes because of obesity and change in lifestyle pattern. 
The symptoms of Type-2 diabetes are similar to Type-1 diabetes but 
are often less marked. Consequently, the disease may be diagnosed 
several years after onset, once complications have become apparent. 
The lack of compliance towards diabetes could lead to chronic 
complications, including macrovascular and microvascular [4]. Most 
of the diabetic patients have relatively poor glycaemic control and 
are presented with multiple co-morbidities like Hypertension, 
Dyslipidemia, Coronary artery disease, etc. 
Diabetes Mellitus mainly occurs in the older age group though 
incidence is now increasing in younger population [5]. As elderly 
diabetic patients have more co-morbid conditions and complications, 
they are prescribed with multidrug regimen making them more prone 
to drug-related problems (DRPs). Therefore polypharmacy should be 
monitored among patients with diabetes as it increases the probability 
of adverse drug events, drug-drug interactions, which escalates the 
drug costs and health care costs leading to poor compliance to 
medications. Administrative databases seem to be useful in analyzing 
trends in the prescribing pattern and cost analysis. 
Hence the drug utilization evaluation (DUE) studies have become 
one of the potential tools in the evaluation of the health system and 
it also suggests modifications in the current prescribing practices to 
the prescribers to encourage rational use of drugs. Therefore, this 
study focuses on evaluating the prescribing pattern, analyzing drug 
related problems, identifying co-morbidities and complications in 
Type 2 Diabetes Mellitus patients and also performing cost analysis 
of Biguanides, Sulphonylureas, Dipeptidyl peptidase-4 inhibitors 
which is one of the components of the Drug utilization metrics 
MATERIALS AND METHODS 
Study site 
The study was conducted at PSG Hospitals, Peelamedu, Coimbatore. 
Study approval 
This study was approved by the Institution Human Ethics 
Committee (IHEC, PSG IMSR) of the hospital. The protocol was 
approved on 08/02/2019, Proposal number: 19/033. 
Study design 
A prospective observational Drug Utilization Evaluation study. 
Study period 
The study was conducted for a period of 6 mo. 
Study subjects 
All T2DM patients who were attending Endocrinology and General 
Medicine departments with co-morbidities were included in this 
International Journal of Pharmacy and Pharmaceutical Sciences 
Print ISSN: 2656-0097 | Online ISSN: 0975-1491                            Vol 13, Issue 3, 2021 
Dawn et al. 
Int J Pharm Pharm Sci, Vol 13, Issue 3, 42-46 
43 
study. Patients of either gender who were above 18 y of age and 
prescribed with Biguanides, Sulphonylureas, DPP4 Inhibitors for 
Type 2 Diabetes Mellitus were included. Diabetic patients who were 
pregnant, lactating, patients taking Insulin analogues and those who 
were not willing to participate in this study were excluded. 
Data collection 
Patients were approached in the respected departments based on the 
inclusion and exclusion criteria. After explaining about the study in a 
regional language, the consent form was collected from the patients 
prior to data collection. Data regarding the socio-demographic and 
clinical characteristics of the patients were obtained through 
interviews and past medical records. From the drug chart review, 
current medications along with dosage, frequency, route of 
administration and duration of therapy have been recorded and 
assessed for drug interactions, adverse drug reactions, polypharmacy, 
prescribing patterns and also for cost analysis. 
Statistics 
The statistical analysis was done using SPSS version 25 and the odds 
ratio 
RESULTS 
In this study, a total of 200 patients were included from the 
departments of Endocrinology and General Medicine of PSG 
Hospitals, Coimbatore. Both Inpatients and Outpatients were 
included. Baseline characteristics such as social habits and gender of 
the patient were summarized in table 1.
 
Table 1: Baseline characteristics 























The age wise distribution of patients with co-morbidities was 
summarized in fig. 1 in which most prevalent co-morbid conditions 
were found in the age group of 51-60 y. Diabetic complications were 
most prevalent in the age group of 51-60 y and patients with a 
diabetic history of 5-10 y were more prone to diabetic complications 
which were summarized in table 2 and table 3. Diabetic 
complications were observed more in smokers therefore, there is an 
association between smoking and diabetic complications (p=0.000).
 
 
Fig. 1: Age wise distribution of patients with co-morbidities 
 
Table 2: Age wise distribution of patients with diabetic complications 
Age group 18-30y 31-40y 41-50y 51-60y 61-70y 71-80y 81-90y 
Retinopathy 0 1 4 12 10 2 0 
Neuropathy 0 3 14 14 10 5 0 
Nephropathy 0 0 2 3 1 1 0 
Foot Ulcer 0 2 3 1 0 1 0 
Total 0 6 23 30 21 9 0 
 
Table 3: Diabetic duration wise distribution of complications 
Diabetic duration Complications Percentage 
<5 y 18 26 
5-10years 34 49 
11-15years 12 17.3 
16-20years 4 5.7 
>20years 1 1.4 
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Fig. 2: Drug class wise distribution of OHAs, The drug classes included in this study were Biguanides, Sulfonyl ureas and DPP4 Inhibitors 
which were summarized in fig. 2 
 
Table 4: Age wise distribution 
Age group Biguanides Sulfonyl ureas DPP-4 inhibitors Combination 
S. U+BG DPP4+BG 
18-30 0 0 0 1 0 
31-40 4 3 0 9 3 
41-50 25 12 4 31 8 
51-60 34 8 0 46 19 
61-70 26 11 2 37 7 
71-80 5 2 5 9 1 
81-90 1 0 0 2 0 
Total (n) 95 36 11 135 38 
Percentage (%) 47.5 18 5.5 67.5 19% 
 
Biguanides were more prescribed in the age group of 51-60 y (n=34, 
17%); Sulfonylureas in the age group of 41-50 y (n=12, 6%) and its 
combination in the age group of 51-60 y(n=46,23%); DPP-4 
Inhibitors in the age group of 71-80 y (n=5, 2.5%) and its 
combination in the age group of 51-60 y (n=19, 9.5%) which are 
illustrated in table 4. 
According to dose wise distribution, the most prescribed doses 
among the OHAs were:  
Biguanides-Metformin 500 mg (n=51, 25.5%); Sulfonyl ureas-
Glimepiride 1 mg (n=6, 3%) and Gliclazide 40 mg (n=6, 3%); DPP4 
Inhibitors-Sitagliptin 25 mg (n=3, 1.5%);Sulfonyl ureas 
Combination–Glimepiride+Metformin 0.5/500 mg (n=22, 11%); 
DPP4 Inhibitors Combination–Vildagliptin+Metformin 50/500 mg 
(n=16, 8%). 
Fig. 3 shows the distribution of the number of Oral Hypoglycemics 
prescribed among patients according to their diabetic history in 
years. 
Out of 200 prescription encounters, Biguanides had 69 plain, 10 
Extended-Release and 12 Sustained Release preparations, 
Sulfonylureas had 7 plain and 2 Extended-Release preparations and 
its combination had 1 plain and 1 Extended Release, DPP4 Inhibitors 
and its combination had only plain formulation.
 
 
Fig. 3: Distribution of OHAs according to diabetic duration 
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Distribution of OHAs according to diabetic duration was 
summarized by fig. 3. 
Out of 200 prescriptions, polypharmacy was seen in 35 (17.5%) 
prescriptions, hyperpolypharmacy in 16 (8%) prescriptions and it 
was high in patients with the age group of 51-60 y. 
Micromedex and Medscape were used to assess drug-drug 
interaction based on its severity and significance. In this study 72 
patients had drug interactions in which 17 were minor, 31 were 
moderate and 28 were major which were clinically significant. As 
more drugs were prescribed in a prescription, more drug 
interactions were encountered. So, there was an association 
between Polypharmacy and DI (p=0.000). 
Out of 200 Diabetic patients, 15 developed ADR in which 10 were 
caused by Metformin, which shows that there is an association 
between drug use and ADR (p=0.017); table 5 depicts the Adverse 
Drug Reaction assessed by using Naranjo’s scale.
 
Table 5: Adverse drug reaction 
ADR assessment by naranjo algorithm 
S. No. Suspected drug Reaction observed Causality assessment (Naranjo scale) No of patients 
1 Glimepiride weight gain Probable 1 
2 Glimepiride weight gain Possible 2 
3 Metformin hypoglycemia Probable 3 
4 Metformin hypoglycemia Possible 5 
5 Metformin GI disturbance Possible 1 
6 Metformin Dyspepsia Definite 2 
7 Vildagliptin burning sensation in feet Possible 1 
The prescriptions were analyzed for WHO core indicators in table 6 
 
Table 6: Prescribing pattern 
Prescribing Indicators Total drugs/Encounters Average percentage (%) WHO ideal values 
Average number of drugs per encounter 997 4.98 1.6-1.8 
Percentage of drugs prescribed by Generic Name 79 7.92 20.0-26.8% 
Percentage of drug encounters with Antibiotics 33 3.3 13.4-24.1% 
Percentage of drug encounters with Injections 77 7.7 100% 
Percentage of drugs prescribed from EML/Formulary 997 100 100% 
 
Cost analysis was done for the selected classes of OHAs which 
showed that combination of DPP-4 Inhibitors 
(Teneligliptin+Metformin) was cheaper when compared to other 
prescribed brands of DPP-4 
Inhibitors (Sitagliptin). It was also found that the most expensive 
brands of DPP-4 Inhibitors (Linagliptin) was less prescribed. 
Metformin was the most prescribed brand and also one of the 
cheapest drugs among OHAs. Cost analysis showed that among 
Sulphonylureas, Glimepiride was the cheapest, but more often, 
Sulphonylureas and Biguanide combinations (Glimepiride+ 
Metformin) were prescribed with reasonable prices. 
DISCUSSION 
In this study, the prevalence of T2DM were more in males 110 
(55%) compared to females 90 (45%), which was in contrast to the 
previous study in which the prevalence of T2DM were more in 
females when compared to males [6]. Hypertension (71%) and 
Dyslipidemia (42.5%) were the most prevalent comorbid conditions 
in the age group of 51-60 y. This was similar to the study conducted 
in 2017 in which hypertension was the most common comorbidity 
observed [7, 8]. Patients with diabetic duration of 5-10 y showed a 
significant effect on the prevalence of Diabetic neuropathy. In this 
study the association between duration of diabetes and risk of 
neuropathy is strong which was in concordance to the previous 
study in which diabetic neuropathy is present mainly in patients 
after 5 y of diabetes history [9,10]. Multidrug Therapy (72.5%) was 
most prescribed among the OHAs followed by Biguanides (33%). 
The most prevalent multidrug therapy was a two-drug combination 
Glimepiride+Metformin (45.5%). This was similar to the previous 
study in which two-drug therapy–Glimepiride+Metformin was most 
prescribed [11]. During this study, 15 ADRs (7.5%) were recorded in 
which the most common were hypoglycaemia (n=8), dyspepsia 
(n=2) and GI disturbances (n=1). This was in concordance with the 
previous study in which hypoglycaemia was the most common ADR 
found [12, 13]. 
Polypharmacy (17.5%) and Hyperpolypharmacy (8%) were 
observed. The maximum level of polypharmacy was observed in the 
age group of 51-60 y followed by patients with the age group of 61-
70 y and 41-50 y. This was in contrast to the previous study in which 
the level of polypharmacy increased with age of patients [13]. The 
Prescribing patterns were evaluated using WHO Core Indicators. 
The average number of drugs per prescription was 4.98%, which 
was higher when compared to WHO Ideal Value (1.6-1.8%), showing 
high degree of polypharmacy. Similarly, the average number of 
drugs per prescription was also higher than the findings of the 
studies conducted in Ayder Referral Hospital of Northern Ethiopia: 
2.61 [14]. Percentage of drugs prescribed by generic name (7.92%) 
was lesser than WHO ideal values (100%), which shows less 
tendency of the prescribers to prescribe drugs by generic names. 
Percentage of injection and antibiotics were 7.7% and 3.3%, 
respectively, which was lesser when compared with WHO Ideal 
Values. This showed less tendency of over usage and prescribing 
expensive drugs. However, the percentage of injection and 
antibiotics were lower when compared to other reports from studies 
conducted in Northern Ethiopia [15]. The percentage of drugs 
prescribed from EML/Formulary was found to be 100%, this shows 
prescribing was based on national essential drug/formulary. Among 
the prescribed brands, DPP4 Inhibitors were of high cost and 
Biguanides were found to be cheaper. Cost analysis also showed that 
Sulphonyl urea-Biguanide combinations and Biguanides were the 
most prescribed and economical. This was in concordance with the 
previous study in which Biguanides and Sulfonyl urea-Biguanide 
combination were most prescribed. Both of these therapies were 
economical and DPP-4 Inhibitors were costlier [16]. The limitation 
of the study was the synthesis of data sources regarding 
pharmacoeconomic evaluation was impossible due to the shorter 
duration of the study. 
CONCLUSION 
This study helped us to find out the current prescribing patterns of 
oral antidiabetic drugs in Type 2 Diabetes Mellitus patients. The 
prescribing trends seems to be progressing towards combination 
therapy predominantly two-drug therapy. Economic burden should 
not affect the treatment regimen of the patient therefore it is the 
physician’s responsibility to be aware of the inter-brand price 
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variations and to prescribe drugs of cheaper prices. Rational drug 
use is a significant factor to be checked for the ideal benefit of drug 
therapy inpatient care.  
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